Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
IPHA Innate Pharma
2.190
-0.100-4.37%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(FY)2020/12/31(FY)2019/12/31(FY)2018/12/31
Total revenue
-78.69% 12.11M -17.60% 56.83M -13.67% 68.97M 144.83% 79.89M
Operating revenue
-78.85% 12.11M -16.19% 57.25M -14.00% 68.31M 145.53% 79.42M
Cost of revenue
-93.26% 3.04M 45.16M
Gross profit
125.87% 53.79M 23.82M
Operating expense
-17.14% 59.94M 42.21% 72.34M -31.95% 50.87M 2.94% 74.75M
Selling and administrative expenses
-38.65% 15.99M -47.43% 26.07M 157.55% 49.58M 18.97% 19.25M
-Selling and marketing expense
-- -- -104.98% -441K 697.84% 8.85M 110.44% 1.11M
-General and administrative expense
-39.67% 15.99M -34.92% 26.51M 124.52% 40.73M 15.89% 18.14M
Research and development costs
-19.81% 47M 3,572.49% 58.61M -97.71% 1.6M 3.81% 69.56M
Depreciation amortization depletion
-- -- -92.28% 1.28M -- 16.53M -- --
-Depreciation and amortization
-- -- -92.28% 1.28M -- 16.53M -- --
Other operating expenses
77.54% -3.06M 19.13% -13.62M -19.77% -16.84M -29.01% -14.06M
Operating profit
-157.87% -47.83M 31.44% -18.55M -625.71% -27.05M 112.87% 5.15M
Net non-operating interest income expense
-93.27% 15K -84.44% 223K 604.58% 1.43M -64.16% -284K
Non-operating interest income
-42.02% 327K -65.19% 564K -- 1.62M -- --
Non-operating interest expense
-8.50% 312K 67.16% 341K 100.00% 204K -9.73% 102K
Total other finance cost
-- -- -- -- -109.34% -17K 203.33% 182K
Other net income (expense)
105.10% 2.33M -1,039.70% -45.66M 326.74% 4.86M 72.74% -2.14M
Gain on sale of security
209.34% 2.33M -143.86% -2.13M 326.74% 4.86M 72.74% -2.14M
Special income (charges)
-- -- -- -43.53M -- -- -- --
-Less:Impairment of capital assets
-- -- -- 43.53M -- -- -- --
Income before tax
28.92% -45.48M -208.22% -63.98M -863.76% -20.76M 105.66% 2.72M
Income tax
0 0 0 -190.49% -333K
Net income
17.47% -52.81M -208.22% -63.98M -780.85% -20.76M 106.30% 3.05M
Net income continuous Operations
28.92% -45.48M -208.22% -63.98M -780.85% -20.76M 106.30% 3.05M
Net income discontinuous operations
-- -7.33M -- -- -- -- -- --
Minority interest income
Net income attributable to the parent company
17.47% -52.81M -208.22% -63.98M -780.85% -20.76M 106.30% 3.05M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
17.47% -52.81M -208.22% -63.98M -780.85% -20.76M 106.30% 3.05M
Basic earnings per share
18.52% -0.66 -161.29% -0.81 -720.00% -0.31 105.62% 0.05
Diluted earnings per share
18.52% -0.66 -161.29% -0.81 -720.00% -0.31 105.62% 0.05
Dividend per share
Currency Unit
EUREUREUREUR
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
Unqualified OpinionUnqualified OpinionUnqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Herv? Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fourni?, and Fran鏾is Romagn? on September 23, 1999 and is headquartered in Marseille, France.
CEO: Dr. Mondher Mahjoubi, M.D.
Market: NASDAQ
Listing Date: 10/17/2019
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist